Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung
Objectives - The biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymis protein 4 (HE4) are useful in the diagnosis, prognosis, and monitoring of non-small cell lung cancer (NSCLC), but their combination has not been investigated yet. The objective of this analysis was to evaluate the...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
19 February 2019
|
| In: |
Lung cancer
Year: 2019, Jahrgang: 130, Pages: 194-200 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2019.02.017 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.lungcan.2019.02.017 Verlag: http://www.sciencedirect.com/science/article/pii/S0169500219303332 
|
| Verfasserangaben: | Thomas Muley, Ying He, Vinzent Rolny, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Michael Meister, Felix J. Herth, Farshid Dayyani |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1688782575 | ||
| 003 | DE-627 | ||
| 005 | 20230427060400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200129s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2019.02.017 |2 doi | |
| 035 | |a (DE-627)1688782575 | ||
| 035 | |a (DE-599)KXP1688782575 | ||
| 035 | |a (OCoLC)1341299818 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Muley, Thomas |e VerfasserIn |0 (DE-588)1056885432 |0 (DE-627)794179169 |0 (DE-576)16759284X |4 aut | |
| 245 | 1 | 0 | |a Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung |c Thomas Muley, Ying He, Vinzent Rolny, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Michael Meister, Felix J. Herth, Farshid Dayyani |
| 246 | 3 | 0 | |a nineteen one twentyone four |
| 264 | 1 | |c 19 February 2019 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.01.2020 | ||
| 520 | |a Objectives - The biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymis protein 4 (HE4) are useful in the diagnosis, prognosis, and monitoring of non-small cell lung cancer (NSCLC), but their combination has not been investigated yet. The objective of this analysis was to evaluate the ability of CYFRA 21-1 and HE4 to predict recurrence as part of follow-up monitoring in patients with adenocarcinoma (ADC) of the lung. - Materials and methods - Serum samples were collected from patients with stage I-IIIA ADC preoperatively and during follow-up at 3, 6, 12, 18, and 24 months and then every 6-12 months up to 5 years post-R0 resection. Samples were analyzed for CYFRA 21-1 and HE4 via electrochemiluminescence immunoassay. All cases of disease recurrence were verified by imaging. The diagnostic performance of CYFRA 21-1, HE4, and their combination to predict recurrence was assessed by Receiver Operating Characteristic (ROC) and corresponding area under the curve (AUC). - Results - 115 patients with ADC were included (N = 612 biomarker measurements); median age was 63 years; most had stage I-II disease (n = 97; 84.3%). All patients underwent surgical resection; 44 patients (38%) also received adjuvant chemotherapy and 16 (14%) received radiation therapy. At the median timepoint for the last blood sample collection (37 months), 31 patients (27%) had experienced recurrence. Both CYFRA 21-1 and HE4 were able to detect recurrence (AUC and 95% confidence interval [CI]): 75.9% (66.0-85.8%) and 75.4% (65.9-84.8%), respectively, but this increased with the combination (78.8% [69.0-88.6%]). At a sensitivity of 80%, the respective specificities (95% CI) for CYFRA 21-1, HE4, and the combination were 57.1% (53.0-61.2%), 57.1% (53.0-61.2%), and 69.7% (65.8-73.4%). - Conclusion - Serial measurements of serum CYFRA 21-1 and HE4 levels could provide a valuable method for follow-up monitoring of patients with ADC to detect recurrence. | ||
| 650 | 4 | |a Adenocarcinoma | |
| 650 | 4 | |a CYFRA 21-1 | |
| 650 | 4 | |a HE4 | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Recurrence | |
| 700 | 1 | |a Warth, Arne |d 1979- |e VerfasserIn |0 (DE-588)132646145 |0 (DE-627)524716927 |0 (DE-576)260019755 |4 aut | |
| 700 | 1 | |a Schneider, Marc |d 1982- |e VerfasserIn |0 (DE-588)140634401 |0 (DE-627)620239948 |0 (DE-576)319208095 |4 aut | |
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 130(2019), Seite 194-200 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung |
| 773 | 1 | 8 | |g volume:130 |g year:2019 |g pages:194-200 |g extent:7 |a Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2019.02.017 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500219303332 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20200129 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 10 | ||
| 998 | |g 140634401 |a Schneider, Marc |m 140634401:Schneider, Marc |d 50000 |e 50000PS140634401 |k 0/50000/ |p 8 | ||
| 998 | |g 132646145 |a Warth, Arne |m 132646145:Warth, Arne |p 6 | ||
| 999 | |a KXP-PPN1688782575 |e 3583093380 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1688782575"],"doi":["10.1016/j.lungcan.2019.02.017"]},"origin":[{"dateIssuedDisp":"19 February 2019","dateIssuedKey":"2019"}],"name":{"displayForm":["Thomas Muley, Ying He, Vinzent Rolny, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Michael Meister, Felix J. Herth, Farshid Dayyani"]},"recId":"1688782575","person":[{"role":"aut","given":"Thomas","family":"Muley","display":"Muley, Thomas"},{"given":"Arne","role":"aut","family":"Warth","display":"Warth, Arne"},{"given":"Marc","role":"aut","family":"Schneider","display":"Schneider, Marc"},{"role":"aut","given":"Felix","family":"Herth","display":"Herth, Felix"}],"title":[{"title":"Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung","title_sort":"Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung"}],"language":["eng"],"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.1985 -"],"language":["eng"],"note":["Gesehen am 20.02.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer","title_sort":"Lung cancer"}],"disp":"Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lungLung cancer","recId":"320649733","part":{"pages":"194-200","volume":"130","extent":"7","text":"130(2019), Seite 194-200","year":"2019"},"origin":[{"dateIssuedKey":"1985","publisher":"Elsevier","dateIssuedDisp":"1985-","publisherPlace":"Amsterdam [u.a.]"}],"id":{"eki":["320649733"],"issn":["1872-8332"],"zdb":["2025812-4"]}}],"note":["Gesehen am 29.01.2020"]} | ||
| SRT | |a MULEYTHOMAPOTENTIALF1920 | ||